Sonali(Mehta)SmithMD

Hematologic Oncology

Elwood V. Jensen Professor of Medicine, Section Chief of Hematology/Oncology, Co-Director of the Lymphoma Program, the University of Chicago Div of the Bio Sci The Pritzker School of Medicine

Join to view full profile

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Smith's full profile

Already have an account?

Office
5841 S Maryland Ave
Chicago, IL 60637
Phone+1 888-824-0200

Fax+1 773-702-3163

Summary

Dr. Sonali Smith is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. She received her medical degree from Northwestern University Feinberg School of Medicine and has been in practice 23 years. She specializes in hematologic oncology and is experienced in Hodgkin and non-Hodgkin lymphoma.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1998 - 2001
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1994 - 1997
Northwestern University The Feinberg School of MedicineClass of 1994

Certifications & Licensure

IL State Medical License 1997 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 2004 May 01
Completed
Phase 1, Phase 2
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors Start of enrollment: 2004 Jun 01
Terminated
Phase 1
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2004 Mar 01
Completed
Phase 2
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2008 Jun 01
Completed
Phase 2
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 Apr 15
Completed
Phase 1, Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Start of enrollment: 2011 Nov 01
Active, not recruiting
Phase 2
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2013 Sep 24
Active, not recruiting
Phase 1
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission Start of enrollment: 2015 Sep 01
Terminated
Phase 2
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda.
Bryan Valcarcel, Kerry J Savage, Brian K Link, John P Leonard, Kara M Kelly
JCO Oncology Practice. 2024-12-06
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.
Paolo Strati, Rebecca Champion, Morton Coleman, Sonali M Smith, Parameswaran Venugopal
British Journal of Haematology. 2024-12-01
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Joseph E Maakaron, Adam Asch, Leslie Popplewell, Graham P Collins, Ian W Flinn
Blood Advances. 2024-11-26

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Sonali (Mehta) Smith, MD, The New England Journal of Medicine
Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell Lymphoma
Jia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood

Abstracts/Posters

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of...
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
Sonali M. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Women Leaders in Oncology® Presents Dr Susan Scott the 2022 WLO "Women Who Conquer Cancer" Young Investigator AwardJune 16th, 2022
ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
Many Patients with Cancer Lack Protection Against Measles, MumpsJuly 30th, 2021
Join now to see all